We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.49%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$214M
AUM Growth
-$13.8M
(-6.1%)
Cap. Flow
+$50.8M
Cap. Flow
% of AUM
23.74%
Top 10 Holdings %
Top 10 Hldgs %
55.85%
Holding
56
New
18
Increased
15
Reduced
11
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$13.7M |
| 2 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$7.82M |
| 3 |
Cue Biopharma
CUE
|
+$6.7M |
| 4 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$6.06M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$5.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARQL
Arqule Inc
ARQL
|
+$8.99M |
| 2 |
United Therapeutics
UTHR
|
+$6.39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$6.02M |
| 4 |
Zimmer Biomet
ZBH
|
+$3.38M |
| 5 |
Envista
NVST
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.8% |
| 2 | Miscellaneous | 4.08% |
| 3 | Technology | 2.61% |
| 4 | Energy | 2.29% |
| 5 | Industrials | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $17.6M | 8.24% |
419,602
+91,473
| +28% | +$4.19M |
|
2
Iovance Biotherapeutics
IOVA
$3.63B
| $16.6M | 7.74% |
553,100
+164,500
| +42% | +$4.36M |
|
3
Kura Oncology
KURA
$1.13B
| $14.4M | 6.74% |
1,450,000
+414,000
| +40% | +$4.74M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $12.6M | 5.88% |
+140,000
| New | +$13.7M |
|
5
uniQure
QURE
$3.38B
| $11.7M | 5.45% |
245,564
+8,064
| +3% | +$463K |
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.8M | 5.06% |
75,000
+12,100
| +19% | +$2.34M |
|
|
7
Zimmer Biomet
ZBH
$19.2B
| $10.6M | 4.96% |
108,150
-25,750
| -19% | -$3.38M |
|
|
8
United Therapeutics
UTHR
$22.1B
| $8.91M | 4.17% |
94,000
-67,195
| -42% | -$6.39M |
|
9
Centene
CNC
$32B
| $8.46M | 3.95% |
142,308
-492
| -0.3% | -$29.9K |
|
|
10
Cue Biopharma
CUE
$203M
| $7.83M | 3.66% |
18,402
+13,814
| +301% | +$6.7M |
|
11
MeiraGTx Holdings
MGTX
$1.33B
| $7.64M | 3.57% |
568,348
+50,504
| +10% | +$853K |
|
|
12
Direxion Daily Small Cap Bear 3x ETF
TZA
$251M
| $7.42M | 3.47% |
+1,563
| New | +$6.06M |
|
13
AC Immune
ACIU
$263M
| $7.32M | 3.42% |
1,058,697
-184,146
| -15% | -$1.44M |
|
14
Cigna
CI
$73.7B
| $6.58M | 3.08% |
37,129
+25,836
| +229% | +$5.01M |
|
|
CHNG
15
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $5.59M | 2.61% |
+559,125
| New | +$7.82M |
|
|
ALBO
16
DELISTED
Albireo Pharma Inc
ALBO
| $5.41M | 2.53% |
330,407
+83,229
| +34% | +$1.83M |
|
17
Aldeyra Therapeutics
ALDX
$89.6M
| $5.03M | 2.35% |
2,035,340
+607,063
| +43% | +$2.73M |
|
|
LHCG
18
DELISTED
LHC Group LLC
LHCG
| $4.89M | 2.29% |
+34,909
| New | +$4.86M |
|
19
AMN Healthcare
AMN
$1.34B
| $4.83M | 2.26% |
+83,471
| New | +$5.71M |
|
|
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
| $4.05M | 1.89% |
+163,708
| New | +$5.96M |
|
21
ADMA Biologics
ADMA
$2.09B
| $3.58M | 1.67% |
+1,242,700
| New | +$4.3M |
|
22
Personalis
PSNL
$1.82B
| $3.35M | 1.56% |
414,740
+8,067
| +2% | +$75K |
|
23
Arrowhead Research
ARWR
$12B
| $3.01M | 1.41% |
+104,737
| New | +$4.22M |
|
24
Encompass Health
EHC
$11.9B
| $3M | 1.4% |
+58,953
| New | +$3.4M |
|
25
UroGen Pharma
URGN
$2.13B
| $2.61M | 1.22% |
146,179
-71,507
| -33% | -$1.93M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2020 Portfolio in Review
As of Q1 2020, Prosight Management held 56 positions worth $214M, down 6.1% from $228M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Prosight Management deployed $50.8M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was United Therapeutics, an estimated $6.39M trimmed.
- Prosight Management's largest Q1 2020 buy was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
- Prosight Management added most to Cue Biopharma in Q1 2020, an estimated $6.7M increase.
- Prosight Management's biggest Q1 2020 reduction was United Therapeutics, cutting an estimated $6.39M.
- Prosight Management fully exited Arqule Inc in Q1 2020, selling an estimated $8.99M.
- Prosight Management's ten largest holdings make up 56% of its $214M portfolio in Q1 2020.
- Prosight Management opened 18 new positions and closed 12 in Q1 2020.
- Prosight Management's portfolio value fell 6.1% quarter-over-quarter to $214M.
Based on Prosight Management's 13F filing for Q1 2020, filed 15 May 2020.